{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:14:57Z","timestamp":1784060097317,"version":"3.55.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunogenicity remains the \u201cAchilles' heel\u201d of protein-based therapeutics. Anti-drug Abs produced in response to protein therapeutics can severely limit both the safety and efficacy of this expanding class of agent. In this article, we report that monotherapy of mice with tofacitinib (the JAK inhibitor) quells Ab responses to an immunotoxin derived from the bacterial protein Pseudomonas exotoxin A, as well as to the model Ag keyhole limpet hemocyanin. Thousand-fold reductions in IgG1 titers to both Ags were observed 21 d post immunization. In fact, suppression was evident for all IgG isotypes and IgM. A reduction in IgG3 production was also noted with a thymus-independent type II Ag. Mechanistic investigations revealed that tofacitinib treatment led to reduced numbers of CD127+ pro\u2013B cells. Furthermore, we observed fewer germinal center B cells and the impaired formation of germinal centers of mice treated with tofacitinib. Because normal Ig levels were still present during tofacitinib treatment, this agent specifically reduced anti-drug Abs, thus preserving the potential efficacy of biological therapeutics, including those used as cancer therapeutics.<\/jats:p>","DOI":"10.4049\/jimmunol.1400063","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T00:27:19Z","timestamp":1401755239000},"page":"48-55","source":"Crossref","is-referenced-by-count":43,"title":["Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts"],"prefix":"10.1093","volume":"193","author":[{"given":"Masanori","family":"Onda","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda , MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[{"name":"Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Steward-Tharp","sequence":"additional","affiliation":[{"name":"Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira H","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda , MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"FitzGerald","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda , MD 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"2025030707194969100_r1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"2025030707194969100_r2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/339394a0","article-title":"A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin","volume":"339","author":"Chaudhary","year":"1989","journal-title":"Nature"},{"key":"2025030707194969100_r3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2025030707194969100_r4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"2025030707194969100_r5","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"2025030707194969100_r6","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"2025030707194969100_r7","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2025030707194969100_r8","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1073\/pnas.0708101104","article-title":"Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707194969100_r9","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","article-title":"Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2025030707194969100_r10","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2025030707194969100_r11","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1073\/pnas.140210597","article-title":"Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity","volume":"97","author":"Tsutsumi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707194969100_r12","doi-asserted-by":"crossref","first-page":"11311","DOI":"10.1073\/pnas.0804851105","article-title":"An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes","volume":"105","author":"Onda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707194969100_r13","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1073\/pnas.1102746108","article-title":"Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes","volume":"108","author":"Onda","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707194969100_r14","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707194969100_r15","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-11-0493","article-title":"Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts","volume":"17","author":"Mossoba","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2025030707194969100_r16","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"2025030707194969100_r17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"2025030707194969100_r18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2025030707194969100_r19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707194969100_r20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.molmed.2004.09.007","article-title":"JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants","volume":"10","author":"Borie","year":"2004","journal-title":"Trends Mol. Med."},{"key":"2025030707194969100_r21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol. Rev."},{"key":"2025030707194969100_r22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"2025030707194969100_r23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be?","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat. Immunol."},{"key":"2025030707194969100_r24","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"2025030707194969100_r25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025030707194969100_r26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"2025030707194969100_r27","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)","volume":"51","author":"Jiang","year":"2008","journal-title":"J. Med. Chem."},{"key":"2025030707194969100_r28","first-page":"5070","article-title":"Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity","volume":"61","author":"Onda","year":"2001","journal-title":"Cancer Res."},{"key":"2025030707194969100_r29","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/1078-0432.CCR-05-0578","article-title":"New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA","volume":"11","author":"Onda","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2025030707194969100_r30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.151.4.853","article-title":"Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency","volume":"151","author":"Slack","year":"1980","journal-title":"J. Exp. Med."},{"key":"2025030707194969100_r31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1600-6143.2003.00281.x","article-title":"The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models","volume":"4","author":"Kudlacz","year":"2004","journal-title":"Am. J. Transplant."},{"key":"2025030707194969100_r32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"key":"2025030707194969100_r33","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.270.5237.794","article-title":"Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3","volume":"270","author":"Thomis","year":"1995","journal-title":"Science"},{"key":"2025030707194969100_r34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nri1780","article-title":"Microenvironmental niches in the bone marrow required for B-cell development","volume":"6","author":"Nagasawa","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707194969100_r35","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/eji.200425217","article-title":"Impaired B-1 and B-2 B cell development and atypical splenic B cell structures in IL-7 receptor-deficient mice","volume":"34","author":"Erlandsson","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"2025030707194969100_r36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.20050158","article-title":"IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF","volume":"201","author":"Kikuchi","year":"2005","journal-title":"J. Exp. Med."},{"key":"2025030707194969100_r37","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1182\/blood.V94.11.3781","article-title":"Lymphoid-restricted development from multipotent candidate murine stem cells: distinct and complimentary functions of the c-kit and flt3-ligands","volume":"94","author":"Borge","year":"1999","journal-title":"Blood"},{"key":"2025030707194969100_r38","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1084\/jem.180.5.1955","article-title":"Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice","volume":"180","author":"Peschon","year":"1994","journal-title":"J. Exp. Med."},{"key":"2025030707194969100_r39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nri2023","article-title":"Interleukin-7 receptor expression: intelligent design","volume":"7","author":"Mazzucchelli","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707194969100_r40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","article-title":"Tofacitinib: a review of its use in adult patients with rheumatoid arthritis","volume":"73","author":"Scott","year":"2013","journal-title":"Drugs"},{"key":"2025030707194969100_r41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-12-0336","article-title":"A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity","volume":"12","author":"Weldon","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"2025030707194969100_r42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1947601910375273","article-title":"A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma","volume":"1","author":"Menges","year":"2010","journal-title":"Genes Cancer"},{"key":"2025030707194969100_r43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-065X.1995.tb00095.x","article-title":"Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development","volume":"148","author":"Leonard","year":"1995","journal-title":"Immunol. Rev."},{"key":"2025030707194969100_r44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000024027","article-title":"Immune response and airway reactivity in wild and IL-4 knockout mice exposed to latex allergens","volume":"118","author":"Xia","year":"1999","journal-title":"Int. Arch. Allergy Immunol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/1\/48\/62227044\/1400063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/1\/48\/62227044\/1400063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:45:47Z","timestamp":1741333547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/193\/1\/48\/7957506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1400063","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7]]},"published":{"date-parts":[[2014,7,1]]}}}